Mogadon (Nitrazepam)

Nitrazepam, the active ingredient in Mogadon, is a benzodiazepine presented as an oral tablet for oral use. It is prescribed to manage insomnia, anxiety disorders, pre‑operative sedation, and as adjunct therapy in epilepsy for adult patients.

GNH USA supplies Mogadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for regulated medicines. Clients benefit from consistent quality, traceability, and support throughout the procurement process globally.

Nitrazepam acts on the central nervous system by enhancing GABA‑mediated inhibition, making it useful for several sleep‑ and anxiety‑related conditions.

- Insomnia: facilitates sleep onset and maintenance in patients with difficulty sleeping. - Anxiety disorders: reduces excessive worry and tension in generalized anxiety. - Preoperative sedation: provides calming effect before surgical procedures. - Adjunct therapy for epilepsy: helps control seizure activity when used with antiepileptic drugs.

Nitrazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: light‑headed sensation or loss of balance. - Headache: mild to moderate head pain. - Fatigue: general lack of energy. - Impaired coordination: reduced motor control.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Depression or suicidal thoughts: mood changes requiring immediate attention. - Paradoxical aggression: increased irritability or hostility. - Dependence and withdrawal: physical reliance after prolonged use.

Before prescribing or dispensing Mogadon, several safety considerations should be observed. - Assess renal and hepatic function: adjust use in patients with impairment. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal. - Use caution in elderly: increased sensitivity to sedation and falls. - Monitor for respiratory depression: especially when combined with other CNS depressants. - Avoid use in patients with narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Store at ambient temperature: keep in the original container, protect from moisture.

Nitrazepam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant CNS depressants (e.g., opioids, barbiturates): may cause profound sedation or respiratory failure. - Alcohol: additive depressant effect increasing risk of overdose. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise nitrazepam plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce nitrazepam levels and effectiveness. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): may increase sedation. - Antihistamines (e.g., diphenhydramine): can enhance drowsiness. - Anticonvulsants (e.g., phenobarbital): may alter seizure control.